Literature DB >> 20670982

Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy.

Robert A Bermel1, Alexander D Rae-Grant, Robert J Fox.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is usually considered a 'young persons' disease', typically presenting between the ages of 20 and 40. In this study we review our experience with patients diagnosed at age 60 or over, with particular emphasis on patients who continue to have evidence of active inflammation despite a later onset.
METHODS: We reviewed all cases of MS diagnosed at or over age 60 in our center over a 5-year period. We identified 111 patients and recorded their clinical and imaging characteristics using prespecified variables. Analyses were performed to describe their interval to diagnosis, clinical syndromes, imaging and laboratory characteristics.
RESULTS: At the time of diagnosis, 8% of patients had a clinically isolated syndrome, 33% were in the relapsing-remitting stage, while 23% had a secondary progressive course, and 32% were primary progressive. Eighty-eight percent of patients had a brain MRI judged 'typical for MS', and 32% of all patients receiving gadolinium had enhanced lesions. Forty-six percent of patients with relapsing-remitting MS or clinically isolated syndrome exhibited gadolinium enhancement. Myelitis was the most common initial clinical syndrome, and progressive myelopathy was a common but not exclusive clinical syndrome at the time of diagnosis.
CONCLUSIONS: A relapsing pattern of MS is not uncommon, even in patients diagnosed over the age of 60. Active inflammation (clinical relapses and gadolinium enhancement) occurs in a significant number of patients with MS with later diagnosis. These observations have implications for evaluation and treatment of patients with MS presenting at an older age.

Entities:  

Mesh:

Year:  2010        PMID: 20670982     DOI: 10.1177/1352458510377334

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

1.  MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada.

Authors:  Dalia L Rotstein; Ruth Ann Marrie; Colleen Maxwell; Sima Gandhi; Susan E Schultz; Kinwah Fung; Karen Tu
Journal:  Neurology       Date:  2019-11-05       Impact factor: 9.910

2.  Accumulation of pTreg cells is detrimental in late-onset (aged) mouse model of multiple sclerosis.

Authors:  Weikan Wang; Rachel Thomas; Jiyoung Oh; Dong-Ming Su
Journal:  Aging Cell       Date:  2022-05-26       Impact factor: 11.005

Review 3.  Epidemiology and treatment of multiple sclerosis in elderly populations.

Authors:  Caila B Vaughn; Dejan Jakimovski; Katelyn S Kavak; Murali Ramanathan; Ralph H B Benedict; Robert Zivadinov; Bianca Weinstock-Guttman
Journal:  Nat Rev Neurol       Date:  2019-06       Impact factor: 42.937

4.  The risk of fracture in patients with multiple sclerosis: the UK general practice research database.

Authors:  Marloes T Bazelier; Tjeerd van Staa; Bernard M J Uitdehaag; Cyrus Cooper; Hubert G M Leufkens; Peter Vestergaard; Joan Bentzen; Frank de Vries
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

5.  Serum 25(OH) Vitamin D levels is not associated with disability in multiple sclerosis patients: A case-control study.

Authors:  Masoud Nikanfar; Ali Akbar Taheri-Aghdam; Maria Yazdani; Sheida Shaafi; Nooshin Masoudian; Hossein Akbari; Parisa Youhanaee; Hamzeh Abbaszadeh
Journal:  Iran J Neurol       Date:  2015-01-05

6.  Is serum vitamin D levels associated with disability in patients with newly diagnosed multiple sclerosis?

Authors:  Hamidreza Hatamian; Elham Bidabadi; Seyed Mohammad Seyed Saadat; Niloufar Seyed Saadat; Ehsan Kazemnezhad; Hamed Ramezani; Babak Bakhshayesh
Journal:  Iran J Neurol       Date:  2013
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.